

## EARLY TERMINATIONS GRANTED—Continued

[12/01/2020 12:00:00 a.m., 12/31/2020 12:00:00 a.m.]

## 12/28/2020

20210205 .....	G	Caesars Entertainment, Inc.; William Hill PLC; Caesars Entertainment, Inc.
20210689 .....	G	Biogen Inc.; Sage Therapeutics, Inc; Biogen Inc.
20210690 .....	G	Thoma Bravo Fund XIII-A, L.P.; Venafi, Inc; Thoma Bravo Fund XIII-A, L.P.
20210691 .....	G	Nasdaq, Inc.; Verafin Holdings, Inc.; Nasdaq, Inc.

## 12/31/2020

20210651 .....	G	Stephen Griggs; AdaptHealth Corp.; Stephen Griggs.
20210652 .....	G	SkyKnight Aero Holdings, LLC; AdaptHealth Corp.; SkyKnight Aero Holdings, LLC.
20210653 .....	G	Peloton Equity AeroCare SPV I, L.P.; AdaptHealth Corp.; Peloton Equity AeroCare SPV I, L.P.

**FOR FURTHER INFORMATION CONTACT:**

Theresa Kingsberry (202–326–3100),  
Program Support Specialist, Federal  
Trade Commission Premerger  
Notification Office, Bureau of  
Competition, Room CC–5301,  
Washington, DC 20024.

By direction of the Commission.

**April J. Tabor,**

*Secretary.*

[FR Doc. 2021–03183 Filed 2–17–21; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—Funding Opportunity Announcement (FOA), RFA OH–21–003, Extension of the World Trade Center Health Registry (U50); Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—Funding Opportunity Announcement (FOA), RFA OH–21–003, Extension of the World Trade Center Health Registry (U50), April 13, 2021; 9:00 a.m.–6:00 p.m., EDT in the original FRN.

The virtual meeting was published in the **Federal Register** on Monday, January 11, 2021, Volume 86, Number 6, page 1976.

The meeting on April 13, 2021 is being amended to change the time and should read as follows:

*Time:* 1:00 p.m.–3:00 p.m., EDT.

The meeting is closed to the public.

**FOR FURTHER INFORMATION CONTACT:**

Marilyn Ridenour B.S.N., M.B.A.,  
M.P.H., C.P.H., C.I.C., CAPT, USPHS,  
Scientific Review Officer, CDC, National  
Institute for Occupational Safety and  
Health, 1095 Willowdale Road, Mailstop

1811, Morgantown, West Virginia  
26505, Telephone (304) 285–5879.

The Director, Strategic Business  
Initiatives Unit, Office of the Chief  
Operating Officer, Centers for Disease  
Control and Prevention, has been  
delegated the authority to sign **Federal  
Register** notices pertaining to  
announcements of meetings and other  
committee management activities, for  
both the Centers for Disease Control and  
Prevention and the Agency for Toxic  
Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Strategic Business Initiatives Unit,  
Office of the Chief Operating Officer, Centers  
for Disease Control and Prevention.*

[FR Doc. 2021–03231 Filed 2–17–21; 8:45 am]

**BILLING CODE 4163–18–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Center for Advancing Translational Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the  
Federal Advisory Committee Act, as  
amended, notice is hereby given of the  
following meeting.

The meeting will be closed to the  
public in accordance with the  
provisions set forth in sections  
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,  
as amended. The grant applications and  
the discussions could disclose  
confidential trade secrets or commercial  
property such as patentable material,  
and personal information concerning  
individuals associated with the grant  
applications, the disclosure of which  
would constitute a clearly unwarranted  
invasion of personal privacy.

*Name of Committee:* National Center for  
Advancing Translational Sciences Special  
Emphasis Panel; CTSA Revision Award.

*Date:* March 9, 2021.

*Time:* 12:00 p.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant  
applications.

*Place:* National Center for Advancing  
Translational Sciences, National Institutes of  
Health, 6701 Democracy Boulevard, Room  
1078, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Rahat (Rani) Khan, Ph.D.,  
Scientific Review Officer, Office of Scientific  
Review, National Center for Advancing  
Translational Sciences, National Institutes of  
Health, 6701 Democracy Boulevard, Room  
1078, Bethesda, MD 20892, 301–894–7319  
[khanr2@csr.nih.gov](mailto:khanr2@csr.nih.gov).

(Catalogue of Federal Domestic Assistance  
Program Nos. 93.859, Pharmacology,  
Physiology, and Biological Chemistry  
Research; 93.350, B—Cooperative  
Agreements; 93.859, Biomedical Research  
and Research Training, National Institutes of  
Health, HHS)

Dated: February 11, 2021.

**David W. Freeman,**

*Program Analyst, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2021–03190 Filed 2–17–21; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Autologous Therapy for the Treatment of Autoimmune Disease Using Chimeric Antigen Receptors Targeting CD19

**AGENCY:** National Institutes of Health,  
HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute,  
an institute of the National Institutes of  
Health, Department of Health and  
Human Services, is contemplating the  
grant of an Exclusive Patent License to  
practice the inventions embodied in the  
Patents and Patent Applications listed  
in the Supplementary Information  
section of this notice to Kyverna  
Therapeutics (“Kyverna”) located in  
Berkeley, CA.